Goldman Sachs Asset Management has agreed to invest $230MM in 4G Clinical, a randomization and trial supply management company.

“As life sciences companies strive for creativity and innovation in trial designs, they cannot afford to be limited by technology,” said Ed Tourtellotte, CTO of 4G Clinical. “Our vision was to build Prancer RTSM to handle any type of trial within any indication. We’ve held to that vision, enabling our biotech and pharma clients to let the science lead.”

“This investment is transformational,” said David Kelleher, CEO of 4G Clinical. “In just over 5 years, 4G Clinical has grown from a start-up to a globally recognized leader in RTSM, helping life sciences organizations execute clinical trials of any size and complexity throughout the drug development lifecycle. To maximize our impact on lives around the globe, we must unwaveringly drive innovation in our technology and processes to tackle clinical trial bottlenecks. This investment from Goldman Sachs ensures that we will not be constrained in any way in that effort.”

“The eClinical Solutions market has expanded rapidly over the past several years with best-in-class, tech-first solutions leading the way, presenting an exciting opportunity for Goldman Sachs,” said Jason Kreuziger, a managing director in Goldman Sachs Asset Management.

“4G Clinical’s established reputation and global reach to date underscores their immense potential over the next few years. We are honored to partner with and help 4G Clinical accelerate their growth,” added Antoine Munfa, a managing director at Goldman Sachs Asset Management.